[Injection aids for intermediate-term acting insulin. Experiences with the OptiPen]

Area of Science:

• Endocrinology
• Diabetes Management
• Medical Devices

Context:

• Conventional insulin therapy often involves multiple daily injections.
• Older diabetic patients may face challenges with traditional insulin administration methods.
• Insulin pens offer a potential alternative for improved patient convenience and adherence.

Purpose:

• To evaluate patient acceptance and the efficacy of the OptiPen injection aid in diabetic patients.
• To assess the impact of the OptiPen on insulin dosage and metabolic control (HbA1c levels).
• To determine the long-term usability and technical reliability of the OptiPen in a real-world clinical setting.

Summary:

• Twenty diabetic patients using conventional insulin (Depot H and/or Basal H Insulin Hoechst) were provided the OptiPen injection aid.
• Seventeen patients expressed a positive opinion and a desire to continue using the OptiPen.
• After approximately 15.6 weeks, mean insulin dosage remained stable, and HbA1c levels showed no significant change in long-term insulin users.
• No long-term technical problems were reported, and the quality of metabolic control was maintained.

Impact:

• The OptiPen facilitates insulin therapy, particularly for older diabetic patients using intermediate-acting or mixed insulin preparations.
• Positive patient reception suggests improved quality of life and adherence to insulin therapy.
• The study indicates that insulin pen technology can be a reliable and effective tool in diabetes management without compromising glycemic control.